Loading... Please wait...

Our Newsletter

NVP-BGT226 | PI3K/mTOR inhibitor

  • NVP-BGT226.jpg
  • NVP-BGT226, 400x400px, png
Catalog #:

Product Description

NVP-BGT226 is a novel orally bioavailable dual PI3K/mTOR inhibitor. It selectively inhibits PI3K and both mTOR complexes mTORC1 and mTORC2, resulting in nearly complete phosphorylation-inhibition of P70S6 and 4E-BP1.

BGT226 demonstrated excellent cellular activities in inhibiting proliferations (IC50: 7-30 nM) of many tested cell lines. Notably, cells that express PIK3CA mutation H1047R are still sensitive to the growth-inhibition of BGT226. Flow cytometric analysis shows accumulation of cells in the G0-G1 phase with concomitant loss in the S-phase. BGT226 induces apoptosis or autophagy of some cancer cells at IC50 less than 25nM. In animal models, BGT226 significantly delays/inhibits tumor growth in a dose-dependent manner. BGT-226 represents a potential candidate for cancer therapy. It has entered phaseI/II clinical trials for treatment of advanced solid tumors (including breast cancer) [1-4].

Technical information:

Chemical Formula:   C28H25F3N6O2.C4H4O4
CAS #:   1245537-68-1
Molecular Weight:   650.6
Purity:   >98%
Appearance:   White
Chemical Name:   8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one Maleic acid
Solubility:   Up to 22 mM in DMSO
Synonyms:   NVP-BGT226, BGT226

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Badura S, et al. Poster Abstracts. Differential Suppressive Effects of Selective PI3K and mTOR and Dual PI3K/mTORC1/C2 Inhibition on Long-Term Cultured Primary Human Acute Lymphoblastic Leukemia (ALL) Cells Implicate a Distinct Role of mTORC2 https://ash.confex.com/ash/2010/webprogram/Paper33127.html
2. Chang KY, et al. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2011. 17(22):7116-26. Pubmed ID: 21976531
3. Baumann P, et al. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012. 23(1):131-8. Pubmed ID: 21959532
4. http://clinicaltrials.gov/ct2/show/NCT00600275

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Find Similar Products by Tag

cancer  mTOR  PI3K  
Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the NVP-BGT226 | PI3K/mTOR inhibitor to your wish list.

You Recently Viewed...